$3.68 Billion Global Cellular Immunotherapy Industry by 2031 – Identifying Growth Segments for Investment – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The report “Cellular Immunotherapy Global Market Report 2022: By Therapy, By Primary, By Application” has been added to from ResearchAndMarkets.com offer.

This report provides strategists, marketers, and senior management with the essential information they need to assess the global cellular immunotherapy market.

The global cellular immunotherapy market is expected to grow from $3.68 billion in 2021 to $4.30 billion in 2022 at a compound annual growth rate (CAGR) of 17%.

The growth is primarily due to businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive lockdown measures involving social distancing, remote work and the closure of business activities that have resulted in operational challenges. The market is expected to reach $7.60 billion in 2026 with a CAGR of 15.3%.

Companies cited

  • Novartis AG

  • Gilead Sciences Inc. (KitePharma)

  • Apac-Biotech

  • Dendreon Pharmaceuticals LLC

  • JW CreaGene Co. Ltd.

  • Green Cross Corp. (GC Pharma)

  • Astra Zeneca

  • Bristol Myers Squibb

  • Pfizer Inc.

  • rock

  • Organic Adicet

  • ResTORbio

  • Céliade

Reasons to buy

  • Gain a truly global perspective with the most comprehensive market report available covering over 12 geographies

  • Understand how the market is affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus diminishes

  • Create regional and national strategies based on local data and analysis

  • Identify growth segments for investment

  • Outperform your competition using forecast data and the drivers and trends shaping the market

  • Understand customers based on the latest market research

  • Benchmark performance against leading competitors

  • Use relationships between key data sets for better strategy

  • Suitable to support your internal and external presentations with reliable high quality data and analysis

The cellular immunotherapy market comprises of revenue generated by companies engaged in the development, manufacture and sale of cellular immunotherapy drugs. Cellular immunotherapy is also known as adoptive cell therapy, a form of treatment that uses immune system cells to eliminate diseases such as non-Hodgkin’s lymphoma, cancer, and acute lymphoblastic leukemia.

The main therapies of cellular immunotherapy are tumor infiltrating lymphocyte (TIL) therapy, modified T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cell therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then injecting them back into patients for treatment. The various primary indications include b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin’s lymphoma, etc. and are used for the treatment of prostate, breast, skin, ovarian, brain tumor, lung and other cancers.

Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. The companies are focusing on the development of new cellular immunotherapies for the treatment of different diseases. The rapid growth in cellular immunotherapy development at the clinical and preclinical stages in 2020 compared to 2019 is expected to broaden the cellular immunotherapy landscape. Subsequently, to generate higher revenue for the cellular immunotherapy market.

The high cost of cellular immunotherapies is expected to hamper the growth of the cellular immunotherapy market. CAR-T therapy is one type of cellular immunotherapy and only two have been approved in the United States. The price of Yescarta and Kymriah is over $350,000 per treatment in the United States, which is very unaffordable for the majority of patients, especially those with low incomes. The high cost of cellular immunotherapies discourages patients from opting for this drug, which has a negative impact on demand and the market.

Companies in the cellular immunotherapy market are focused on the development of ready-to-use allogeneic therapies for new and improved cancer treatment. Ready-to-use allogeneic therapies are produced from donor cells instead of patient cells as in the case of autologous therapy. Their non-customized nature provides advantages such as cost effectiveness, large scale production, speed and quality control.

For more information about this report visit https://www.researchandmarkets.com/r/avt27i

Back To Top